Early malaria infection, dysregulation of angiogenesis, metabolism and inflammation across pregnancy, and risk of preterm birth in Malawi: A cohort study.


Journal

PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360

Informations de publication

Date de publication:
10 2019
Historique:
received: 05 02 2019
accepted: 21 08 2019
entrez: 2 10 2019
pubmed: 2 10 2019
medline: 6 2 2020
Statut: epublish

Résumé

Malaria in pregnancy is associated with adverse birth outcomes. However, the underlying mechanisms remain poorly understood. Tight regulation of angiogenic, metabolic, and inflammatory pathways are essential for healthy pregnancies. We hypothesized that malaria disrupts these pathways leading to preterm birth (PTB). We conducted a secondary analysis of a randomized trial of malaria prevention in pregnancy conducted in Malawi from July 21, 2011, to March 18, 2013. We longitudinally assessed circulating mediators of angiogenic, metabolic, and inflammatory pathways during pregnancy in a cohort of HIV-negative women (n = 1,628), with a median age of 21 years [18, 25], and 562 (35%) were primigravid. Pregnancies were ultrasound dated, and samples were analyzed at 13 to 23 weeks (Visit 1), 28 to 33 weeks (Visit 2), and/or 34 to 36 weeks (Visit 3). Malaria prevalence was high; 70% (n = 1,138) had PCR-positive Plasmodium falciparum infection at least once over the course of pregnancy and/or positive placental histology. The risk of delivering preterm in the entire cohort was 20% (n = 304/1506). Women with malaria before 24 weeks gestation had a higher risk of PTB (24% versus 18%, p = 0.005; adjusted relative risk [aRR] 1.30, 95% confidence interval [CI] 1.04-1.63, p = 0.021); and those who were malaria positive only before week 24 had an even greater risk of PTB (28% versus 17%, p = 0.02; with an aRR of 1.67, 95% CI 1.20-2.30, p = 0.002). Using linear mixed-effects modeling, malaria before 24 weeks gestation was associated with altered kinetics of inflammatory (C-Reactive Protein [CRP], Chitinase 3-like protein-1 [CHI3L1], Interleukin 18 Binding Protein [IL-18BP], soluble Tumor Necrosis Factor receptor II [sTNFRII], soluble Intercellular Adhesion Molecule-1 [sICAM-1]), angiogenic (soluble Endoglin [sEng]), and metabolic mediators (Leptin, Angiopoietin-like 3 [Angptl3]) over the course of pregnancy (χ2 > 13.0, p ≤ 0.001 for each). Limitations include being underpowered to assess the impact on nonviable births, being unable to assess women who had not received any antimalarials, and, because of the exposure to antimalarials in the second trimester, there were limited numbers of malaria infections late in pregnancy. Current interventions for the prevention of malaria in pregnancy are initiated at the first antenatal visit, usually in the second trimester. In this study, we found that many women are already malaria-infected by their first visit. Malaria infection before 24 weeks gestation was associated with dysregulation of essential regulators of angiogenesis, metabolism, and inflammation and an increased risk of PTB. Preventing malaria earlier in pregnancy may reduce placental dysfunction and thereby improve birth outcomes in malaria-endemic settings.

Sections du résumé

BACKGROUND
Malaria in pregnancy is associated with adverse birth outcomes. However, the underlying mechanisms remain poorly understood. Tight regulation of angiogenic, metabolic, and inflammatory pathways are essential for healthy pregnancies. We hypothesized that malaria disrupts these pathways leading to preterm birth (PTB).
METHODS AND FINDINGS
We conducted a secondary analysis of a randomized trial of malaria prevention in pregnancy conducted in Malawi from July 21, 2011, to March 18, 2013. We longitudinally assessed circulating mediators of angiogenic, metabolic, and inflammatory pathways during pregnancy in a cohort of HIV-negative women (n = 1,628), with a median age of 21 years [18, 25], and 562 (35%) were primigravid. Pregnancies were ultrasound dated, and samples were analyzed at 13 to 23 weeks (Visit 1), 28 to 33 weeks (Visit 2), and/or 34 to 36 weeks (Visit 3). Malaria prevalence was high; 70% (n = 1,138) had PCR-positive Plasmodium falciparum infection at least once over the course of pregnancy and/or positive placental histology. The risk of delivering preterm in the entire cohort was 20% (n = 304/1506). Women with malaria before 24 weeks gestation had a higher risk of PTB (24% versus 18%, p = 0.005; adjusted relative risk [aRR] 1.30, 95% confidence interval [CI] 1.04-1.63, p = 0.021); and those who were malaria positive only before week 24 had an even greater risk of PTB (28% versus 17%, p = 0.02; with an aRR of 1.67, 95% CI 1.20-2.30, p = 0.002). Using linear mixed-effects modeling, malaria before 24 weeks gestation was associated with altered kinetics of inflammatory (C-Reactive Protein [CRP], Chitinase 3-like protein-1 [CHI3L1], Interleukin 18 Binding Protein [IL-18BP], soluble Tumor Necrosis Factor receptor II [sTNFRII], soluble Intercellular Adhesion Molecule-1 [sICAM-1]), angiogenic (soluble Endoglin [sEng]), and metabolic mediators (Leptin, Angiopoietin-like 3 [Angptl3]) over the course of pregnancy (χ2 > 13.0, p ≤ 0.001 for each). Limitations include being underpowered to assess the impact on nonviable births, being unable to assess women who had not received any antimalarials, and, because of the exposure to antimalarials in the second trimester, there were limited numbers of malaria infections late in pregnancy.
CONCLUSIONS
Current interventions for the prevention of malaria in pregnancy are initiated at the first antenatal visit, usually in the second trimester. In this study, we found that many women are already malaria-infected by their first visit. Malaria infection before 24 weeks gestation was associated with dysregulation of essential regulators of angiogenesis, metabolism, and inflammation and an increased risk of PTB. Preventing malaria earlier in pregnancy may reduce placental dysfunction and thereby improve birth outcomes in malaria-endemic settings.

Identifiants

pubmed: 31574087
doi: 10.1371/journal.pmed.1002914
pii: PMEDICINE-D-19-00421
pmc: PMC6772002
doi:

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1002914

Subventions

Organisme : CIHR
ID : FDN-148439
Pays : Canada

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

PLoS One. 2012;7(11):e48763
pubmed: 23155405
N Engl J Med. 2016 Mar 10;374(10):928-39
pubmed: 26962728
Trans R Soc Trop Med Hyg. 2003 Mar-Apr;97(2):236-41
pubmed: 14584384
J Infect Dis. 1999 Jun;179(6):1580-3
pubmed: 10228088
PLoS One. 2013 Dec 27;8(12):e84181
pubmed: 24386348
J Matern Fetal Neonatal Med. 2010 Dec;23(12):1384-99
pubmed: 20459337
PLoS One. 2010 Mar 01;5(3):e9481
pubmed: 20208992
PLoS One. 2011;6(9):e24985
pubmed: 21966395
Malar J. 2018 Feb 15;17(1):82
pubmed: 29448936
Reprod Sci. 2009 Feb;16(2):206-15
pubmed: 19208789
Am J Pathol. 2008 Jan;172(1):77-85
pubmed: 18156205
Am J Epidemiol. 1993 Sep 1;138(5):318-25
pubmed: 8356970
J Pediatr. 2017 Feb;181:309-318.e1
pubmed: 27806833
PLoS Med. 2016 Sep 13;13(9):e1002124
pubmed: 27622558
Malar J. 2013 Apr 24;12:139
pubmed: 23617626
PLoS Pathog. 2013 Feb;9(2):e1003153
pubmed: 23408887
Am J Obstet Gynecol. 2017 Dec;217(6):684.e1-684.e17
pubmed: 29031892
Front Med (Lausanne). 2017 Jul 25;4:117
pubmed: 28791290
Lancet. 2012 Jun 9;379(9832):2162-72
pubmed: 22682464
PLoS One. 2011;6(12):e28540
pubmed: 22174834
Lancet Infect Dis. 2007 Feb;7(2):93-104
pubmed: 17251080
Trans R Soc Trop Med Hyg. 2012 Sep;106(9):570-2
pubmed: 22818740
Biol Reprod. 2000 Nov;63(5):1219-28
pubmed: 11058523
Placenta. 2015 Aug;36(8):960-6
pubmed: 26094029
Drug Saf. 2007;30(6):481-501
pubmed: 17536875
Malar J. 2013 Jun 04;12:183
pubmed: 23734718
Cochrane Database Syst Rev. 2014 Oct 10;(10):CD000169
pubmed: 25300703
PLoS Med. 2012;9(8):e1001292
pubmed: 22904691
Curr Probl Pediatr Adolesc Health Care. 2011 Jul;41(6):158-76
pubmed: 21684471
PLoS Med. 2009 Dec;6(12):e1000191
pubmed: 19956761
Angiogenesis. 2007;10(3):149-66
pubmed: 17457680
J Ultrasound Med. 1991 Oct;10(10):557-61
pubmed: 1942221
Biol Reprod. 2006 Feb;74(2):218-29
pubmed: 16267210
Trans R Soc Trop Med Hyg. 2010 Jun;104(6):416-22
pubmed: 20207387
Sci Rep. 2019 Feb 19;9(1):2260
pubmed: 30783215
Malar J. 2008 Jan 29;7:26
pubmed: 18230163
Malar J. 2016 Feb 16;15:92
pubmed: 26879849
BMC Med. 2017 Jun 21;15(1):117
pubmed: 28633672
Semin Fetal Neonatal Med. 2006 Oct;11(5):309-16
pubmed: 16828580
Am J Pathol. 2006 Nov;169(5):1886-98
pubmed: 17071609
PLoS One. 2015 Aug 06;10(8):e0134619
pubmed: 26247200
Gynecol Endocrinol. 2017 Sep;33(9):668-674
pubmed: 28447504
J Matern Fetal Neonatal Med. 2008 Jan;21(1):9-23
pubmed: 18175241
J Immunol. 2010 Dec 1;185(11):7115-22
pubmed: 20980627
Cell Host Microbe. 2013 Feb 13;13(2):215-26
pubmed: 23414761
Trop Med Int Health. 2000 Mar;5(3):167-73
pubmed: 10747278
CMAJ. 2016 Jul 12;188(10):736-746
pubmed: 26644500
BMC Cell Biol. 2008 Sep 02;9:47
pubmed: 18764931
Am J Obstet Gynecol. 2014 Nov;211(5):509.e1-8
pubmed: 24881826
PLoS Med. 2006 Nov;3(11):e446
pubmed: 17105340
Lancet Infect Dis. 2018 Apr;18(4):e107-e118
pubmed: 29396010
Microcirculation. 2014 Jan;21(1):15-25
pubmed: 23981199
Circ Res. 2002 Sep 6;91(5):441-8
pubmed: 12215494
J Turk Ger Gynecol Assoc. 2016 Dec 01;17(4):182-185
pubmed: 27990085
J Huazhong Univ Sci Technolog Med Sci. 2007 Feb;27(1):9-12
pubmed: 17393097
Am J Trop Med Hyg. 1996;55(1 Suppl):33-41
pubmed: 8702035
Malar J. 2012 Sep 10;11:319
pubmed: 22963509
Lancet. 2015 Dec 19;386(10012):2507-19
pubmed: 26429700
PLoS One. 2010 Dec 29;5(12):e15291
pubmed: 21209923
Life Sci. 2017 Apr 15;175:52-60
pubmed: 28336397
JAMA. 2013 Feb 13;309(6):594-604
pubmed: 23403684
Matern Child Health J. 2015 Nov;19(11):2366-74
pubmed: 26152889
Malar J. 2014 Jul 21;13:279
pubmed: 25047113
Malar J. 2010 Aug 16;9:233
pubmed: 20712868
Immunology. 1994 Dec;83(4):665-9
pubmed: 7533138
Infect Immun. 2008 Apr;76(4):1527-34
pubmed: 18212078
Ultrasound Obstet Gynecol. 2016 Dec;48(6):719-726
pubmed: 26924421
Sci Transl Med. 2018 Mar 7;10(431):
pubmed: 29514999
Cytokine Growth Factor Rev. 2017 Jun;35:71-84
pubmed: 28285098
Front Physiol. 2013 May 28;4:122
pubmed: 23755018
BMJ. 2017 Aug 17;358:j3677
pubmed: 28819030
Biomark Res. 2017 Dec 13;5:34
pubmed: 29255607
Int J Mol Sci. 2018 Feb 01;19(2):null
pubmed: 29389861
Malar J. 2012 Mar 16;11:71
pubmed: 22433778
Angiogenesis. 2005;8(2):157-67
pubmed: 16211358
Trans R Soc Trop Med Hyg. 2000 Sep-Oct;94(5):477-83
pubmed: 11132370

Auteurs

Robyn E Elphinstone (RE)

Sandra Rotman Centre for Global Health, University Health Network-University of Toronto, Toronto, Ontario, Canada.

Andrea M Weckman (AM)

Sandra Rotman Centre for Global Health, University Health Network-University of Toronto, Toronto, Ontario, Canada.

Chloe R McDonald (CR)

Sandra Rotman Centre for Global Health, University Health Network-University of Toronto, Toronto, Ontario, Canada.

Vanessa Tran (V)

Sandra Rotman Centre for Global Health, University Health Network-University of Toronto, Toronto, Ontario, Canada.

Kathleen Zhong (K)

Sandra Rotman Centre for Global Health, University Health Network-University of Toronto, Toronto, Ontario, Canada.

Mwayiwawo Madanitsa (M)

College of Medicine, University of Malawi, Blantyre, Malawi.

Linda Kalilani-Phiri (L)

College of Medicine, University of Malawi, Blantyre, Malawi.

Carole Khairallah (C)

Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.

Steve M Taylor (SM)

Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Division of Infectious Diseases and Duke Global Health Institute, Duke University, Durham, North Carolina, United States of America.

Steven R Meshnick (SR)

Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.

Victor Mwapasa (V)

College of Medicine, University of Malawi, Blantyre, Malawi.

Feiko O Ter Kuile (FO)

Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.

Andrea L Conroy (AL)

Department of Pediatrics, Indiana University School of Medicine, Indianapolis, United States of America.

Kevin C Kain (KC)

Sandra Rotman Centre for Global Health, University Health Network-University of Toronto, Toronto, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH